News|Articles|August 20, 2025

Should Chest CT be Routine for Prostate Cancer Patients on Androgen Deprivation Therapy?

Nine months after initiation of androgen deprivation therapy (ADT), prostate cancer patients with higher myocardial extracellular volume (ECV) — derived from chest contrast-enhanced CT — had over a fourfold higher risk for major adverse cardiovascular events (MACEs), according to new research.

For patients receiving androgen deprivation therapy (ADT) for prostate cancer (PCa), emerging research affirms that assessing myocardial extracellular volume (ECV) from chest contrast-enhanced computed tomography (CECT) may provide significant utility in monitoring for cardiotoxicity and predicting major adverse cardiovascular events (MACEs).